Global biotechnology company Mereon Bio LLC, based in the United States, announced on
Tuesday, it has strategically transferred its next-generation core drug-release
technologies to South Korea’s network-based healthtech platform company Unexa Korea.
The technology transfer is part of a new industrial initiative aimed at expanding Mereon’s
highly sophisticated drug-delivery mechanisms into more accessible, everyday health-care
consumer products.
Mereon Bio possesses three advanced core technologies applicable to the next-generation
health-care market: a reversible ion-network-based drug-release platform, an electrically
controlled sustained-release system, and a micro-mechanical stimulus-responsive release
technology. The company has actively engaged in joint research and supply collaborations
with global pharmaceutical companies based on these technologies. Until now, the
technologies have largely been confined to hospital and specialty pharmaceutical
applications, but the transfer marks a turning point in bringing them to a broader consumer
base as daily health solutions.
A Mereon Bio official said the company has long focused on developing “drugs that act
longer and are delivered with greater precision,” adding that “the true impact of technology is
realized only when it becomes accessible to everyone.” The official noted that the transfer to
Unexa Korea goes beyond technological advancement and enables the creation of new
value centered on everyday health that anyone can easily access.
Unexa Korea aims to implement advanced health-care products not merely as items for sale,
but as health technologies integrated into individuals’ habits and daily lives, leveraging its
IT-based platform operation capabilities. Following the technology acquisition, Mereon’s
advanced release technologies may be applied to Unexa’s planned functional product
lineup, raising expectations for formulation designs that emphasize greater convenience and
sustainability.
Mereon Bio expects the transfer to help its core technologies secure multiple consumer
touchpoints in the Korean market, while expanding real-world validation and
commercialization through Unexa Korea’s distribution infrastructure. Industry observers
suggest the move could serve as a meaningful complement to Mereon’s traditionally
B2B-focused strategy.
“Technology should not belong to anyone, but should exist for everyone, and only when
technology meets distribution is an ecosystem truly completed,” the company said. “This
partnership reflects an important decision aligned with Mereon’s philosophy of extending
technology into everyday life.”
Following the completion of the transfer process, Mereon Bio plans to work with Unexa
Korea to unveil technology-based new products within the next 12 months, while also
pursuing additional joint research and global technology partnerships.
